ReviewDigestive diseases and sciences2016
Innate Immunity and Inflammation in NAFLD/NASH.
Review in Digestive diseases and sciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 277 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
277 citing papers in PubMed, 5 syntheses or guidelines pooled it, 481 citations in OpenAlex.
- Association between blood cell count inflammatory biomarkers and non-alcoholic fatty liver disease: A systematic review and meta-analysis.Endocrine · 2026Pooled it
- Mapping the global research output of Traditional Chinese Medicine in the treatment of metabolic dysfunction-associated steatotic liver disease: a comprehensive bibliometric analysis based on multiple databases (2000-2025).Frontiers in medicine · 2026Pooled it
- The association between immunoinflammatory biomarkers NLR, PLR, LMR and nonalcoholic fatty liver disease: a systematic review and meta-analysis.Clinical and experimental medicine · 2025Pooled it
- Association between hepatic steatosis and lipoprotein(a) levels in non-alcoholic patients: A systematic review.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2024Pooled it
- Association of Inflammatory Cytokines With Non-Alcoholic Fatty Liver Disease.Frontiers in immunology · 2022Pooled it
- Association between dietary fatty acids and all-cause mortality in patients with cirrhosis: A cohort study.Experimental physiology · 2026Article
- Dietary index for gut microbiota, plasma metabolome, and risks of metabolic dysfunction-associated steatotic liver disease and other chronic liver diseases.Nutrition & metabolism · 2026Article
- Extracellular Vesicle fromInternational journal of molecular sciences · 2026Article
- Kv1.3 regulates macrophage immune function through PI3K/AKT signaling pathway to alleviate metabolic dysfunction-associated steatohepatitis.Journal of molecular medicine (Berlin, Germany) · 2026Article
- Determinants of Liver Steatosis Progression in Chinese Children: A Prospective Cohort Study.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Article
- Identification of candidate biomarkers for NAFLD through bioinformatics analysis and machine learning based on circulating insulin degradation-associated genes.Frontiers in endocrinology · 2026Article
- Risk factors for pulmonary function alterations in children with metabolic dysfunction-associated fatty liver disease.Scientific reports · 2025Article
- Fructose and follistatin potentiate acute MASLD during complete hepatic insulin resistance.Nature communications · 2025Article
- Translational framework linking perfluoroheptanoic acid (PFHpA) exposure to metabolic dysfunction associated steatotic liver disease in adolescents.Communications medicine · 2025Article
- Perturbation of Circulating Inflammatory Proteins Mediates the Relationship Between Cholecystectomy and Nonalcoholic Fatty Liver Disease: A Multivariate and Mediation Mendelian Randomization Study.Health science reports · 2025Article
- Discovery of novel FABP1 inhibitors for the treatment of metabolic dysfunction-associated steatohepatitis and hepatic fibrosis.BMC chemistry · 2025Article
- The Combination Empagliflozin/Metformin Attenuates the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease in a Diet-Induced Experimental Rat Model.International journal of molecular sciences · 2025Article
- Association of CALLY index with NAFLD in U.S. adults from NHANES 2017-2020 assessed by vibration-controlled transient elastography.Diabetology & metabolic syndrome · 2025Article
- Association of alpha-1 acid glycoprotein with hepatic steatosis and liver fibrosis among women: a population-based study.BMC gastroenterology · 2025Article
- Induction of Autophagy as a Therapeutic Breakthrough for NAFLD: Current Evidence and Perspectives.Biology · 2025Review
217 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
Abstract
Inflammation and hepatocyte injury and death are the hallmarks of nonalcoholic steatohepatitis (NASH), the progressive form of nonalcoholic fatty liver disease (NAFLD), which is a currently burgeoning public health problem. Innate immune activation is a key factor in triggering and amplifying hepatic inflammation in NAFLD/NASH. Thus, identification of the underlying mechanisms by which immune cells in the liver recognize cell damage signals or the presence of pathogens or pathogen-derived factors that activate them is relevant from a therapeutic perspective. In this review, we present new insights into the factors promoting the inflammatory response in NASH including sterile cell death processes resulting from lipotoxicity in hepatocytes as well as into the altered gut-liver axis function, which involves translocation of bacterial products into portal circulation as a result of gut leakiness. We further delineate the key immune cell types involved and how they recognize both damage-associated molecular patterns or pathogen-associated molecular patterns through binding of surface-expressed pattern recognition receptors, which initiate signaling cascades leading to injury amplification. The relevance of modulating these inflammatory signaling pathways as potential novel therapeutic strategies for the treatment of NASH is summarized.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.